Merck & Co Inc
MRK86.600USD
-3.160-3.52%
Handelsschluss 04/02, 16:00（ET）Kurse um 15 Minuten verzögert
218.89BMarktkapitalisierung
12.79KGV TTM
mehr Informationen über Merck & Co Inc Unternehmen
Merck & Co., Inc. is a research-intensive biopharmaceutical company engaged in research to deliver health solutions that advance the prevention and treatment of diseases in people and animals. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It is also engaged in developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyl transferase.
Unternehmensinformationen
Unternehmens-codeMRK
Name des UnternehmensMerck & Co Inc
IPO-datumJan 01, 1941
Gegründet am1970
CEOMr. Robert M. (Rob) Davis
Anzahl der mitarbeiter75000
WertpapierartOrdinary Share
GeschäftsjahresendeJan 01
Addresse2000 Galloping Hill Road
StadtKENILWORTH
BörseNYSE Consolidated
LandUnited States of America
Postleitzahl07033
Telefon19087404000
Websitehttps://www.merck.com/
Unternehmens-codeMRK
IPO-datumJan 01, 1941
Gegründet am1970
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
+27.35%
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
78.86K
+70.54%
Ms. Caroline Litchfield
Ms. Caroline Litchfield
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
74.34K
+46.03%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
66.61K
+73.22%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
53.42K
+90.81%
Mr. Michael A. Klobuchar
Mr. Michael A. Klobuchar
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
23.22K
+1.98%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
20.72K
+5.86%
Ms. Patricia F. Russo
Ms. Patricia F. Russo
Independent Director
Independent Director
13.15K
--
Mr. Thomas Henry (Tom) Glocer, J.D.
Mr. Thomas Henry (Tom) Glocer, J.D.
Lead Independent Director
Lead Independent Director
5.10K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
+27.35%
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
78.86K
+70.54%
Ms. Caroline Litchfield
Ms. Caroline Litchfield
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
74.34K
+46.03%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
66.61K
+73.22%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
53.42K
+90.81%
Umsatzaufteilung
Währung: USDUpdate-Zeit: 3 hours ago
Währung: USDUpdate-Zeit: 3 hours ago
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Oncology-Keytruda
29.48B
45.95%
Vaccines -Gardasil/Gardasil
8.58B
13.38%
Animal Health-Livestock
3.46B
5.39%
Other pharmaceutical
2.51B
3.91%
Vaccines -ProQuad/M-M-R II/Varivax
2.48B
3.87%
Other
17.65B
27.50%
Nach RegionUSD
Name
Umsatz
Anteil
United States
32.28B
50.30%
Europe, Middle East and Africa
14.04B
21.88%
China
5.49B
8.56%
Latin America
3.46B
5.39%
Japan
3.28B
5.11%
Other
5.62B
8.75%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Oncology-Keytruda
29.48B
45.95%
Vaccines -Gardasil/Gardasil
8.58B
13.38%
Animal Health-Livestock
3.46B
5.39%
Other pharmaceutical
2.51B
3.91%
Vaccines -ProQuad/M-M-R II/Varivax
2.48B
3.87%
Other
17.65B
27.50%
Aktionäre
Update-Zeit: Tue, Mar 11
Update-Zeit: Tue, Mar 11
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
10.03%
BlackRock Institutional Trust Company, N.A.
5.68%
State Street Global Advisors (US)
4.79%
Wellington Management Company, LLP
3.20%
Geode Capital Management, L.L.C.
2.42%
Other
73.89%
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
10.03%
BlackRock Institutional Trust Company, N.A.
5.68%
State Street Global Advisors (US)
4.79%
Wellington Management Company, LLP
3.20%
Geode Capital Management, L.L.C.
2.42%
Other
73.89%
Art
Aktionäre
Anteil
Investment Advisor/Hedge Fund
35.88%
Investment Advisor
31.49%
Research Firm
3.76%
Pension Fund
2.96%
Bank and Trust
2.38%
Hedge Fund
1.52%
Sovereign Wealth Fund
1.49%
Insurance Company
0.69%
Family Office
0.11%
Other
19.72%
Institutionelle Beteiligung
Update-Zeit: Thu, Feb 20
Update-Zeit: Thu, Feb 20
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
5308
2.05B
81.06%
+16.18M
2024Q4
5410
2.04B
80.88%
+11.87M
2024Q3
5200
2.01B
79.47%
-7.96M
2024Q2
5181
2.01B
79.28%
-4.86M
2024Q1
5154
2.00B
78.88%
-6.10M
2023Q4
5065
1.99B
78.60%
+584.81K
2023Q3
4871
1.98B
78.17%
-32.03M
2023Q2
4864
2.00B
78.94%
-18.54M
2023Q1
4818
1.99B
78.43%
-16.95M
2022Q4
4785
1.98B
77.94%
-5.23M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
253.26M
10.03%
+3.27M
+1.31%
Feb 28, 2025
BlackRock Institutional Trust Company, N.A.
143.39M
5.68%
+10.26M
+7.71%
Dec 31, 2024
State Street Global Advisors (US)
120.91M
4.79%
+1.88M
+1.58%
Dec 31, 2024
Wellington Management Company, LLP
80.74M
3.2%
+4.93M
+6.51%
Dec 31, 2024
Geode Capital Management, L.L.C.
61.18M
2.42%
+2.03M
+3.43%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
34.98M
1.38%
+1.17M
+3.47%
Dec 31, 2024
Fidelity Management & Research Company LLC
33.58M
1.33%
-11.95M
-26.24%
Dec 31, 2024
BofA Global Research (US)
23.08M
0.91%
-1.38M
-5.65%
Dec 31, 2024
BlackRock Asset Management Ireland Limited
21.22M
0.84%
+1.34M
+6.77%
Dec 31, 2024
Morgan Stanley Smith Barney LLC
20.63M
0.82%
-290.99K
-1.39%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: 15 hours ago
Update-Zeit: 15 hours ago
Name
Anteil
FT Vest DJIA Dogs 10 Target Income ETF
11.99%
First Trust NASDAQ Pharmaceuticals ETF
6.57%
ProShares Pet Care ETF
5.23%
TBG Dividend Focus ETF
4.77%
Amplify Weight Loss Drug & Treatment ETF
4.76%
VanEck Pharmaceutical ETF
4.61%
Invesco Pharmaceuticals ETF
4.51%
Tema Oncology ETF
4.49%
ProShares Smart Materials ETF
4.3%
Proshares Ultra Health Care
4.3%
Mehr Anzeigen
FT Vest DJIA Dogs 10 Target Income ETF
Anteil11.99%
First Trust NASDAQ Pharmaceuticals ETF
Anteil6.57%
ProShares Pet Care ETF
Anteil5.23%
TBG Dividend Focus ETF
Anteil4.77%
Amplify Weight Loss Drug & Treatment ETF
Anteil4.76%
VanEck Pharmaceutical ETF
Anteil4.61%
Invesco Pharmaceuticals ETF
Anteil4.51%
Tema Oncology ETF
Anteil4.49%
ProShares Smart Materials ETF
Anteil4.3%
Proshares Ultra Health Care
Anteil4.3%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
35.12B
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Jan 28, 2025
MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Apr 07, 2025 going ex on Mar 17, 2025
Mar 17, 2025
Apr 07, 2025
Mar 17, 2025
Nov 19, 2024
MRK.NB Final Cash Dividend of gross USD 0.81 paid on Jan 08, 2025 going ex on Dec 16, 2024
Dec 16, 2024
Jan 08, 2025
Dec 16, 2024
Jul 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Oct 07, 2024 going ex on Sep 16, 2024
Sep 16, 2024
Oct 07, 2024
Sep 16, 2024
May 29, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Jul 08, 2024 going ex on Jun 17, 2024
Jun 17, 2024
Jul 08, 2024
Jun 17, 2024
Jan 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Apr 05, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Apr 05, 2024
Mar 14, 2024
Nov 28, 2023
MRK.NB Final Cash Dividend of gross USD 0.77 paid on Jan 08, 2024 going ex on Dec 14, 2023
Dec 15, 2023
Jan 08, 2024
Dec 14, 2023
Jul 25, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Oct 06, 2023 going ex on Sep 14, 2023
Sep 15, 2023
Oct 06, 2023
Sep 14, 2023
May 23, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Jul 10, 2023 going ex on Jun 14, 2023
Jun 15, 2023
Jul 10, 2023
Jun 14, 2023
Jan 24, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Apr 10, 2023 going ex on Mar 14, 2023
Mar 15, 2023
Apr 10, 2023
Mar 14, 2023
Nov 30, 2022
MRK.NB Final Cash Dividend of gross USD 0.73 paid on Jan 09, 2023 going ex on Dec 14, 2022
Dec 15, 2022
Jan 09, 2023
Dec 14, 2022
Mehr Anzeigen
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten